Literature DB >> 18403751

Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.

Margarita Gutova1, Joseph Najbauer, Richard T Frank, Stephen Edward Kendall, Anna Gevorgyan, Marianne Z Metz, Mark Guevorkian, Marissa Edmiston, Donghong Zhao, Carlotta A Glackin, Seung U Kim, Karen S Aboody.   

Abstract

Human neural and mesenchymal stem cells have been identified for cell-based therapies in regenerative medicine and as vehicles for delivering therapeutic agents to areas of injury and tumors. However, the signals required for homing and recruitment of stem cells to these sites are not well understood. Urokinase plasminogen activator (uPA) and urokinase plasminogen activator receptor (uPAR) are involved in chemotaxis and cell guidance during normal development and are upregulated in invasive tumors. Here we provided evidence that activation of uPA and uPAR in malignant solid tumors (brain, lung, prostate, and breast) augments neural and mesenchymal stem cell tropism. Expression levels of uPAR on human solid tumor cell lines correlated with levels of uPA and soluble uPAR in tumor cell-conditioned media. Cytokine expression profiles of these tumor-conditioned media were determined by protein arrays. Among 79 cytokines investigated, interleukin (IL)-6, IL-8, and monocyte chemoattractant protein-1 were the most highly expressed cytokines in uPAR-positive tumors. We provided evidence that human recombinant uPA induced stem cell migration, whereas depletion of uPA from PC-3 prostate cancer cell-conditioned medium blocked stem cell migration. Furthermore, retrovirus-mediated overexpression of uPA and uPAR in neuroblastoma (NB1691) cells induced robust migration of stem cells toward NB1691 cell-conditioned media, compared with media derived from wild-type NB1691 cells. We conclude that expression of uPA and uPAR in cancer cells underlies a novel mechanism of stem cell tropism to malignant solid tumors, which may be important for development of optimal stem cell-based therapies. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18403751     DOI: 10.1634/stemcells.2008-0141

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  47 in total

Review 1.  Mesenchymal stem cells in the pathogenesis and therapy of breast cancer.

Authors:  Christelle P El-Haibi; Antoine E Karnoub
Journal:  J Mammary Gland Biol Neoplasia       Date:  2010-12-21       Impact factor: 2.673

Review 2.  Novel treatment strategies for malignant gliomas using neural stem cells.

Authors:  Michael C Oh; Daniel A Lim
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

3.  Optical imaging of progenitor cell homing to patient-derived tumors.

Authors:  Isabel G Newton; Warren C Plaisted; Steven Messina-Graham; Annelie E Abrahamsson Schairer; Alice Y Shih; Evan Y Snyder; Catriona H M Jamieson; Robert F Mattrey
Journal:  Contrast Media Mol Imaging       Date:  2012 Nov-Dec       Impact factor: 3.161

4.  Magnetic resonance imaging tracking of ferumoxytol-labeled human neural stem cells: studies leading to clinical use.

Authors:  Margarita Gutova; Joseph A Frank; Massimo D'Apuzzo; Vazgen Khankaldyyan; Megan M Gilchrist; Alexander J Annala; Marianne Z Metz; Yelena Abramyants; Kelsey A Herrmann; Lucy Y Ghoda; Joseph Najbauer; Christine E Brown; M Suzette Blanchard; Maciej S Lesniak; Seung U Kim; Michael E Barish; Karen S Aboody; Rex A Moats
Journal:  Stem Cells Transl Med       Date:  2013-09-06       Impact factor: 6.940

5.  Mesenchymal stem cell-based cell engineering with multifunctional mesoporous silica nanoparticles for tumor delivery.

Authors:  Xinglu Huang; Fan Zhang; Hui Wang; Gang Niu; Ki Young Choi; Magdalena Swierczewska; Guofeng Zhang; Haokao Gao; Zhe Wang; Lei Zhu; Hak Soo Choi; Seulki Lee; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2012-12-08       Impact factor: 12.479

Review 6.  Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells.

Authors:  Fatemeh Norozi; Ahmad Ahmadzadeh; Saeid Shahrabi; Tina Vosoughi; Najmaldin Saki
Journal:  Tumour Biol       Date:  2016-07-20

7.  Iron labeling and pre-clinical MRI visualization of therapeutic human neural stem cells in a murine glioma model.

Authors:  Mya S Thu; Joseph Najbauer; Stephen E Kendall; Ira Harutyunyan; Nicole Sangalang; Margarita Gutova; Marianne Z Metz; Elizabeth Garcia; Richard T Frank; Seung U Kim; Rex A Moats; Karen S Aboody
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

8.  Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma.

Authors:  Ivy A W Ho; Kelly Y W Chan; Wai-Hoe Ng; Chang M Guo; Kam M Hui; Philip Cheang; Paula Y P Lam
Journal:  Stem Cells       Date:  2009-06       Impact factor: 6.277

9.  Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression.

Authors:  H Chen; J Hao; L Wang; Y Li
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

10.  Neural stem cells as a novel platform for tumor-specific delivery of therapeutic antibodies.

Authors:  Richard T Frank; Marissa Edmiston; Stephen E Kendall; Joseph Najbauer; Chia-Wei Cheung; Thewodros Kassa; Marianne Z Metz; Seung U Kim; Carlotta A Glackin; Anna M Wu; Paul J Yazaki; Karen S Aboody
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.